KoAct Bio Healthcare Active Surpasses 200 Billion Won in Net Assets

Samsung Active Asset Management announced on September 5 that the net asset value of 'KoAct Bio Healthcare Active', Korea's first bio active ETF, has surpassed 200 billion won, reaching 202 billion won.

This product was the first to be launched under Samsung Active Asset Management's independent ETF brand, KoAct, and has shown steady growth since its listing in August 2023. Its differentiated active management has also delivered outstanding returns. Over the past month, it recorded a return of 10.2%. Among domestic bio and healthcare sector ETFs, it ranked first in terms of returns.

KoAct Bio Healthcare Active is the first active ETF in Korea to invest in the bio healthcare sector. In the era of an aging population, it invests in bio healthcare companies expected to achieve high growth through the integration of artificial intelligence (AI) technology. Based on financial indicators and industry data analysis, the fund identifies companies with high growth potential through analyst research and company visits. It has secured stability by applying a thorough risk management system to the highly volatile bio sector. The ETF also pursues sustainable performance by reflecting both short-term momentum and long-term growth potential.

Major holdings include: ABL Bio (12.5%), Alteogen (10.2%), Ligochem Bio (9.4%), Samsung Biologics (6.7%), SK Biopharmaceuticals (6.5%), Celltrion (4.77%), and ST Pharm (4.5%).

Globally, the intensification of aging populations, increased healthcare spending, and the acceleration of AI-based new drug development are converging to make healthcare a key industry for structural growth. In the United States, there is active development of global new drug pipelines such as anticancer and obesity treatments. Gene therapies and mRNA-based treatments are also entering the commercialization stage.

Going forward, the announcement of large-scale clinical trial results by global pharmaceutical companies, advances in convergence technologies between AI and bio, and the development of gene therapies and new vaccines are all expected to further accelerate the growth of the healthcare industry. Samsung Active Asset Management plans to proactively capture these market changes and reflect them in ETF management, while continuously expanding its differentiated active ETF lineup centered on the KoAct series.

Shim Juhyun, manager at Samsung Active Asset Management, introduced the KoAct Bio Healthcare Active ETF as "a product that delivers differentiated performance to investors by reflecting the structural growth of the global healthcare industry." He added, "We will continue to strive to establish this ETF as a trusted long-term product through thorough research and systematic risk management."